RxDoctor Payments Data

Frantz Francisque

Hematology & Oncology · Brooksville, FLNPI 1902217953

Payments from drug & device makers

$20,486in general payments, 2019–2025

Across 817 payments — averaging $25.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Geron Corporation$3K
  • Novartis$2K
  • Bristol Myers Squibb$1K
  • AstraZeneca$990
  • Gilead$917
  • Pfizer$869
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$2,08010%
  • Speaking & faculty fees$2251%
  • Travel & lodging$6193%
  • Food & beverage$16,27679%
  • Education$6043%
  • Other$6823%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Geron Corporation10$2,933
Novartis76$2,069
Bristol Myers Squibb73$1,473
AstraZeneca46$990
Gilead(2 entities)38$917
Pfizer61$869
Astellas Pharma US Inc33$840
Bayer34$733
Johnson & Johnson30$667
E.r. Squibb & Sons, L.L.C.33$624
Merck28$619
Eisai Inc.29$582
Daiichi Sankyo Inc.26$549
Incyte Corporation21$456
Tempus AI, Inc14$444
GSK24$429
Regeneron Healthcare Solutions, Inc.16$408
EMD Serono, Inc.17$393
Lilly USA, LLC18$364
Genentech USA, Inc.13$278
Fennec Pharmaceuticals, Inc.14$273
Array Biopharma Inc13$252
AbbVie11$241
Seagen Inc.11$235
Beigene USA, Inc.4$192
Takeda Pharmaceuticals U.S.A., Inc.6$191
Sanofi6$148
Karyopharm Therapeutics Inc.7$138
Sun Pharmaceutical Industries Inc.6$128
AVEO Pharmaceuticals, Inc.6$127
Sobi, Inc5$116
Celltrion USA Inc.2$114
Pharmacosmos Therapeutics Inc.6$112
Rigel Pharmaceuticals, Inc.7$103
Servier Pharmaceuticals LLC5$99
Puma Biotechnology, Inc.5$96
G1 Therapeutics, Inc.5$88
Stemline Therapeutics Inc.4$86
Sumitomo Pharma America, Inc.5$78
Boehringer Ingelheim3$77
Kyowa Kirin, Inc.3$67
Pharmaessentia USA Corporation3$65
Jazz Pharmaceuticals Inc.2$61
Mirati Therapeutics, Inc.3$60
Verity Pharmaceuticals Inc.4$60
Pharmacyclics LLC, An Abbvie Company2$52
Springworks Therapeutics, Inc.2$51
Genmab U.S., Inc.3$51
Beone Medicines USA, Inc.2$49
Ipsen Biopharmaceuticals, Inc2$39
Taiho Oncology, Inc.2$39
Tersera Therapeutics LLC1$37
Janssen Scientific Affairs, LLC1$32
Caris MPI, Inc.1$24
Legend Biotech USA Inc.1$23
Telix Pharmaceuticals1$22
Alnylam Pharmaceuticals Inc.1$21
Deciphera Pharmaceuticals Inc.1$21
Morphosys, US Inc.1$20
Blueprint Medicines Corporation1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,486 in reported general payments places this provider in the 50th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$1,166,911
Medicare patients
237
Services billed
64,824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide40$412,669
JakafiRuxolitinib Phosphate14$377,154
PromactaEltrombopag Olamine13$314,699
XtandiEnzalutamide17$238,502
BrukinsaZanubrutinib11$156,114
EliquisApixaban66$50,062
XareltoRivaroxaban33$37,305
Imatinib Mesylate22$11,978
Abiraterone Acetate15$10,501
Tranexamic Acid25$2,971
Ondansetron OdtOndansetron55$2,947
Letrozole67$2,871
Oxycodone Hcl75$2,052
Levofloxacin24$624
Cyclosporine ModifiedCyclosporine, Modified11$623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$456$377,15414 claims
NovartisPromacta$2,069$314,69913 claims
Astellas Pharma US IncXtandi$840$238,50217 claims
Beigene USA, Inc.Brukinsa$192$156,11411 claims
PfizerEliquis$869$50,06266 claims
Johnson & JohnsonXarelto$667$37,30533 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$32$10,50115 claims
Lilly USA, LLCOlanzapine$364$18917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Brooksville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →